|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,618.00 GBX | +1.32% |
|
+0.23% | +0.17% |
| 06:04pm | Stocks mixed, French political drama continues | AN |
| 02:08pm | AstraZeneca Says Imfinzi Approved in US for Limited-Stage Small Cell Lung Cancer | MT |
| Capitalization | 207B 195B 182B 162B 290B 17,501B 321B 2,247B 833B 7,170B 775B 759B 31,018B | P/E ratio 2024 * |
24.5x | P/E ratio 2025 * | 20.3x |
|---|---|---|---|---|---|
| Enterprise value | 229B 217B 202B 180B 322B 19,417B 356B 2,492B 925B 7,954B 860B 842B 34,414B | EV / Sales 2024 * |
4.32x | EV / Sales 2025 * | 3.93x |
| Free-Float |
96.63% | Yield 2024 * |
2.33% | Yield 2025 * | 2.45% |
More valuation ratios
* Estimated data
More news
Last Transcript: AstraZeneca PLC
More recommendations
More press releases
More news
| 1 day | +0.97% | ||
| 1 week | +0.23% | ||
| Current month | +0.06% | ||
| 1 month | +4.98% | ||
| 3 months | -15.33% | ||
| 6 months | -15.16% | ||
| Current year | +0.17% |
1 week
10 416.00
10 804.00
1 month
9 670.0010 804.00
Current year
9 461.0013 388.00
1 year
9 461.0013 388.00
3 years
8 090.3213 388.00
5 years
5 871.0013 388.00
10 years
3 680.0013 388.00
| Director | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 30/09/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 31/07/2021 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 31/12/2019 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 05/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 64 | 30/09/2012 |
Philip Broadley
BRD | Director/Board Member | 63 | 26/04/2017 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 8.29% | 55 M€ | +4.64% | - | |
| 5.39% | 203 M€ | +13.92% | ||
| 5.17% | 20 M€ | +16.82% | - | |
| 4.89% | 831 M€ | +13.88% |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.32% | +0.23% | +4.67% | +26.96% | 207B | ||
| -0.65% | +4.05% | +40.71% | +235.96% | 747B | ||
| -1.15% | +3.13% | +12.21% | +117.61% | 487B | ||
| -0.89% | -3.64% | -5.80% | -8.33% | 362B | ||
| -0.77% | -3.97% | +21.51% | +44.76% | 312B | ||
| +1.20% | +1.16% | -3.21% | +40.04% | 256B | ||
| +1.02% | +0.95% | +2.13% | -30.27% | 231B | ||
| +0.31% | -3.21% | +6.25% | +21.10% | 204B | ||
| -1.08% | -2.45% | +1.87% | +32.16% | 150B | ||
| +1.21% | -2.17% | -11.86% | -50.19% | 143B | ||
| Average | -0.00% | -0.41% | +6.85% | +42.98% | 309.88B | |
| Weighted average by Cap. | -0.26% | +0.85% | +13.38% | +82.41% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 53.07B 50.21B 46.67B 41.61B 74.46B 4,496B 82.43B 577B 214B 1,842B 199B 195B 7,969B | 56.96B 53.89B 50.08B 44.65B 79.91B 4,826B 88.46B 619B 230B 1,977B 214B 209B 8,552B |
| Net income | 8.36B 7.91B 7.35B 6.55B 11.73B 708B 12.98B 90.92B 33.73B 290B 31.38B 30.71B 1,255B | 10.15B 9.6B 8.92B 7.95B 14.24B 860B 15.76B 110B 40.93B 352B 38.08B 37.27B 1,523B |
| Net Debt | 22.62B 21.4B 19.89B 17.73B 31.73B 1,916B 35.12B 246B 91.24B 785B 84.89B 83.08B 3,396B | 17.01B 16.09B 14.95B 13.33B 23.86B 1,441B 26.41B 185B 68.62B 590B 63.84B 62.48B 2,554B |
More financial data
* Estimated data
Employees
89,900
Sector
Pharmaceuticals
Calendar
07/12/2024
- BMO Oncology Summit
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/24 | 10,618.00 p | +1.32% | 1,458,917 |
| 04/12/24 | 10,480.00 p | -2.87% | 4,060,643 |
| 03/12/24 | 10,790.00 p | +2.24% | 2,193,681 |
| 02/12/24 | 10,554.00 p | -0.55% | 1,931,094 |
| 29/11/24 | 10,612.00 p | +0.17% | 2,380,553 |
Delayed Quote London S.E., December 05, 2024 at 04:35 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
133.26USD
Average target price
177.00USD
Spread / Average Target
+32.83%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AZN Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition